6 Stocks Make It On Today's Healthcare & Biotech Stock Watchlist
Powered by HealthTechMovers.com
We added 6 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Stryker, SYK
Summary: Stryker Corporation is one of the world's leading medical technology companies and together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes.
- Last Price: $248.31
- Price Change: -$21.72, -8.0435%
- Yearly Gain: -5.47%
- Market Cap: $93.79B
- P/E Ratio: 47.623
Here are 3rd party ratings for SYK:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Bottom 42% (147 out of 253)
What is the sentiment on the street regarding Stryker ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Low
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Positive
If you are interested in SYK or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on SYK before you decide to make any investment.
Click here for chart >>
Agilent, A
Summary: Agilent Technologies Inc. focuses its expertise on six key markets: Food; Environmental and Forensics; Pharmaceutical; Diagnostics; Chemical and Energy; and Research. Agilent helps ensure that their global food supply is free of contaminants, whether chemical, viral, bacterial or microbiological. The Company's customers include government regulators and labs that control food safety, as well as private companies that produce, package and sell food to the public. Agilent has one of the broadest solutions portfolios of any company serving the pharmaceutical industry. Its solutions provide precise answers for every segment of the pharmaceutical industry, from disease research and drug discovery to drug development, manufacturing and quality control. Agilent gives doctors a head start in the fight against cancer and other diseases. Agilent's immunohistochemistry (IHC) products provide high staining quality, improved standardization and increased efficiency enabling the ultimate goal of increased patient safety.
- Last Price: $121.32
- Price Change: -$3.97, -3.1686%
- Yearly Gain: -11.18%
- Market Cap: $36.41B
- P/E Ratio: 30.717
Here are 3rd party ratings for A:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 32% (82 out of 253)
What is the sentiment on the street regarding Agilent ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Positive
If you are interested in A or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on A before you decide to make any investment.
Click here for chart >>
Amicus, FOLD
Summary: Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.'The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.'The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.'The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.
- Last Price: $7.83
- Price Change: -$0.22, -2.7329%
- Yearly Gain: -22.63%
- Market Cap: $2.19B
- P/E Ratio: -8.443
Here are 3rd party ratings for FOLD:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Bottom 45% (139 out of 253)
What is the sentiment on the street regarding Amicus ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Neutral
If you are interested in FOLD or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on FOLD before you decide to make any investment.
Click here for chart >>
Prothena, PRTA
Summary: Prothena Corporation plc is a biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies for disease-causing proteins. The Company is developing the following programs: NEOD001 for Amyloidosis, NEOD002 for Parkinson's disease, MCAM for Inflammatory disease and Metastatic Cancer and Tau for Alzheimer's disease. Prothena Corporation plc is headquartered in Dublin, Ireland.
- Last Price: $33.33
- Price Change: -$1.53, -4.389%
- Yearly Gain: 31.06%
- Market Cap: $1.56B
- P/E Ratio: 23.906
Here are 3rd party ratings for PRTA:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 45% (139 out of 253)
What is the sentiment on the street regarding Prothena ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Positive
If you are interested in PRTA or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on PRTA before you decide to make any investment.
Click here for chart >>
908 Devices, MASS
Summary: 908 Devices Inc. is a purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis. It conducts research, designs and manufactures products of mass spectrometry, microfluidic separations, software automation and machine learning. 908 Devices Inc. is headquartered in Boston.
- Last Price: $18.28
- Price Change: -$0.89, -4.6427%
- Yearly Gain: -66.42%
- Market Cap: $573.70M
- P/E Ratio: -22.861
Here are 3rd party ratings for MASS:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 35% (165 out of 253)
What is the sentiment on the street regarding 908 Devices ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Very Positive
If you are interested in MASS or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on MASS before you decide to make any investment.
Click here for chart >>
Clene, CLNN
Summary: Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I Limited, is based in SALT LAKE CITY.
- Last Price: $2.87
- Price Change: -$0.13, -4.3333%
- Yearly Gain: -69.53%
- Market Cap: $181.52M
- P/E Ratio: -16.608
Here are 3rd party ratings for CLNN:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 45% (139 out of 253)
What is the sentiment on the street regarding Clene ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: No Signal
If you are interested in CLNN or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CLNN before you decide to make any investment.
Click here for chart >>
Thanks for reading!